Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now

Stock Information for Agenus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Agenus Inc.

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.